BeyondSpring (BYSI) Cash from Operations (2016 - 2026)
BeyondSpring (BYSI) posted Cash from Operations of 3277000.0 for Q1 2026, up 40.46% sequentially from 5504000.0 in Q4 2025, and up 21.94% YoY from 2687408.87 in Q1 2025.
BeyondSpring (BYSI) Cash from Operations (2016 - 2026) Analysis & Trends
BeyondSpring has reported Cash from Operations for 9 years, with the latest figure at 3277000.0 in Q1 2026.
- Quarterly Cash from Operations rose 21.94% year-over-year to 3277000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 18848000.0 (down 22.61% YoY) and the FY2025 annual result came in at 19769000.0, down 20.23% from the prior year.
- Cash from Operations improved to 3277000.0 in Q1 2026 per BYSI's latest filing, from 5504000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 982000.0 in Q4 2024 and troughed at 6985000.0 in Q2 2024.
- A 3-year average of 4387666.67 and a median of 5171000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2025 and 2026: Cash from Operations tumbled 660.49% in 2025, then rose 21.94% in 2026.
- Over 3 years, Cash from Operations stood at 982000.0 in 2024, then sank by 660.49% to 5504000.0 in 2025, then soared by 40.46% to 3277000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 3277000.0, 5504000.0, and 4193000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | BeyondSpring | 30.22 Mn | 30.22 Mn | - | -3.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.77 Mn |
| Jun 30, 2026 | -3.77 Mn |
| Mar 31, 2026 | -3.28 Mn |
| Mar 31, 2026 | -3.28 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Sep 30, 2025 | -4.19 Mn |
| Sep 30, 2025 | -4.19 Mn |
| Jun 30, 2025 | -5.87 Mn |
| Jun 30, 2025 | -5.87 Mn |
| Mar 31, 2025 | -4.20 Mn |
| Mar 31, 2025 | -4.20 Mn |
| Dec 31, 2024 | 982,000.00 |
| Dec 31, 2024 | 982,000.00 |
| Sep 30, 2024 | -5.17 Mn |
| Sep 30, 2024 | -5.17 Mn |
| Jun 30, 2024 | -6.99 Mn |
| Jun 30, 2024 | -6.99 Mn |
| Mar 31, 2024 | -5.27 Mn |
| Mar 31, 2024 | -5.27 Mn |